MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319832 | Name: Turofexorate isopropyl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Turofexorate isopropyl (XL335 or WAY-362450) is a potent, selective agonist of the farnesoid X receptor (FXR), a nuclear receptor central to bile acid homeostasis, lipid metabolism, and glucose regulation. Preclinical research demonstrates its efficacy in lowering cholesterol and triglyceride levels, reducing atherosclerotic lesions, and protecting against ferroptosis-induced cell death. Though clinical trials for hyperlipidemia treatment were discontinued, its potential applications in metabolic disorders and tumor modulation through FXR-related pathways remain of significant interest.

Chemical Structure

Turofexorate isopropyl
Turofexorate isopropyl
CAS#629664-81-9

Theoretical Analysis

MedKoo Cat#: 319832

Name: Turofexorate isopropyl

CAS#: 629664-81-9

Chemical Formula: C25H24F2N2O3

Exact Mass: 438.1755

Molecular Weight: 438.47

Elemental Analysis: C, 68.48; H, 5.52; F, 8.67; N, 6.39; O, 10.95

Price and Availability

Size Price Availability Quantity
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,650.00 2 Weeks
1g USD 3,850.00 2 Weeks
2g USD 6,450.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
WAY-362450; WAY362450; WAY 362450; XL335; XL 335; XL-335; FXR450; FXR-450; FXR 450; Turofexorate isopropyl.
IUPAC/Chemical Name
Isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino(4,5-b)indole-5- carboxylate
InChi Key
INASOKQDNHHMRE-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H24F2N2O3/c1-14(2)32-24(31)17-12-29(23(30)15-9-10-18(26)19(27)11-15)13-25(3,4)21-16-7-5-6-8-20(16)28-22(17)21/h5-12,14,28H,13H2,1-4H3
SMILES Code
O=C(C1=CN(C(C2=CC=C(F)C(F)=C2)=O)CC(C)(C)C3=C1NC4=C3C=CC=C4)OC(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 438.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Manley S, Ding W. Role of farnesoid X receptor and bile acids in alcoholic liver disease. Acta Pharm Sin B. 2015 Mar;5(2):158-67. doi: 10.1016/j.apsb.2014.12.011. Epub 2015 Mar 9. Review. PubMed PMID: 26579442; PubMed Central PMCID: PMC4629219. 2: Wu WB, Xu YY, Cheng WW, Wang YX, Liu Y, Huang D, Zhang HJ. Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta--a study on maternal cholestasis model. Placenta. 2015 May;36(5):545-51. doi: 10.1016/j.placenta.2015.02.005. Epub 2015 Feb 17. PubMed PMID: 25747729. 3: Liu X, Xue R, Ji L, Zhang X, Wu J, Gu J, Zhou M, Chen S. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochem Biophys Res Commun. 2014 Jul 18;450(1):117-23. doi: 10.1016/j.bbrc.2014.05.072. Epub 2014 May 27. PubMed PMID: 24875360. 4: Baghdasaryan A, Chiba P, Trauner M. Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med. 2014 Jun;37:57-76. doi: 10.1016/j.mam.2013.12.001. Epub 2013 Dec 12. Review. PubMed PMID: 24333169; PubMed Central PMCID: PMC4045202. 5: Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun. 2014 Jan 3;443(1):68-73. doi: 10.1016/j.bbrc.2013.11.057. Epub 2013 Nov 20. PubMed PMID: 24269813. 6: Li WH, Fu J, Zheng MY, Liu GX, Tang Y. [Progress in the ligands and their complex structures of farnesoid X receptor]. Yao Xue Xue Bao. 2012 Jun;47(6):704-15. Review. Chinese. PubMed PMID: 22919716. 7: Mehlmann JF, Crawley ML, Lundquist JT 4th, Unwalla RJ, Harnish DC, Evans MJ, Kim CY, Wrobel JE, Mahaney PE. Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR). Bioorg Med Chem Lett. 2009 Sep 15;19(18):5289-92. doi: 10.1016/j.bmcl.2009.07.148. Epub 2009 Aug 3. PubMed PMID: 19683924. 8: Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009 Aug;51(2):380-8. doi: 10.1016/j.jhep.2009.03.025. Epub 2009 May 18. PubMed PMID: 19501927. 9: Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res. 2009 Jun;50(6):1090-100. doi: 10.1194/jlr.M800619-JLR200. Epub 2009 Jan 27. PubMed PMID: 19174369; PubMed Central PMCID: PMC2681391. 10: Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, Foster P, Li J, Pircher P, Petrowski M, Schulman I, Westin S, Wrobel J, Yan G, Bischoff E, Daige C, Mohan R. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem. 2009 Feb 26;52(4):904-7. doi: 10.1021/jm8014124. PubMed PMID: 19159286. 11: Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, Harnish DC. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G543-52. doi: 10.1152/ajpgi.90585.2008. Epub 2009 Jan 8. PubMed PMID: 19136377. 12: Zhang S, Liu Q, Wang J, Harnish DC. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem Biophys Res Commun. 2009 Feb 6;379(2):476-9. doi: 10.1016/j.bbrc.2008.12.117. Epub 2008 Dec 30. PubMed PMID: 19118524.

View History

Cystamine

Cystamine

Featured